COVID-19 pandemic shifted epidemiology for cancer screening sites: breast, cervix, colon, and rectum by Yevgeniy Ishkinin, Dilyara Kaidarova, Dilyara Kaidarova, Serzhan Nazarbek, Serzhan Nazarbek, Alma Zhylkaidarova, Saniya Ossikbayeva, Kamilla Mussina, Nazgul Omarbayeva

Subjects: Get full text

Extensive Morphea Following Adjuvant Radiotherapy for Breast Carcinoma—Case Report by Alexandru Panaitescu, Hannah Nguyen, Laurence Masson-Côté, Carolina Lucena Fernandes

Subjects: Get full text

A specific information-based multi-modal network (SIM-Net) for accurate diagnosis of breast lesions in multiparametric MRI: A multi-center study by Yunsong Peng, Yu Zheng, Lulu Han, Liangquan Sun

Subjects: “…Breast cancer…”
Get full text

Do non-mammary conditions influence patients’ cosmetic perception after breast conserving surgery? by Idam de Oliveira-Junior, Idam de Oliveira-Junior, Fabíola Cristina Brandini da Silva, Fabíola Cristina Brandini da Silva, Almir José Sarri, René Aloísio da Costa Vieira, René Aloísio da Costa Vieira

Subjects: “…breast cancer…”
Get full text

Genetic trends and common BRCA1/2 pathogenic sequence variants in black African and Indian breast cancer patients presenting at Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa by M Makhetha, C Aldous, N Chabilal

Subjects: “…Breast cancer…”
Get full text

COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland by Piotr Kosiorek, Bożena Mikołuć, Samuel Stróż, Anna Hryniewicz, Dorota E. Kazberuk, Robert Milewski, Anna Grzeszczuk, Magdalena J. Borkowska, Anna Stasiak‐Barmuta

Subjects: “…Breast cancer…”
Get full text

Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome by Khaled Abd Elaziz Ahmed Elnaghi, Hosam Ali Alghanmi, Shereef Ahmed Elsamany, Fathia Almarzoki, Mohamed Elsafty, Mohammad Jaffal

“…CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. …”
Get full text

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer by Kaewkedsri P, Intarawichian P, Jessadapattarakul S, Kunprom W, Koonmee S, Thanee M, Somintara O, Wongbuddha A, Chadbunchachai P, Nawapun S, Aphivatanasiri C

Subjects: “…triple-negative breast cancer…”
Get full text

A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair by Xingxing Li, Yue Wu, Min Zhang, Fengliang Wang, Hong Yin, Yanrong Zhang, Shuli Zhao, Jiehua Ma, Mingming Lv, Cheng Lu

“…PDBAG1 has demonstrated substantial efficacy in suppressing triple‐negative breast cancer (TNBC) both in vitro and in vivo. Its mechanism of action involves mitochondrial impairment and the inhibition of oxidative phosphorylation (OXPHOS), achieved through direct binding to C1QBP, thereby promoting its ubiquitin‐dependent degradation. …”
Get full text

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status by Sanaa Gamrani, Laila Akhouayri, Sara Boukansa, Mehdi Karkouri, Hinde El Fatemi

“…We elaborated on their complete immunohistochemical profile based on the main breast cancer biomarkers: Ki-67, HER2, estrogen, and progesterone receptors. …”
Get full text

Synthesis, Characterization, and Crystal Structures of Bis-Imidazolium Salts and Respective Dinuclear Ag(I) N-Heterocyclic Carbene Complexes: In Vitro Anticancer Studies against “Human Colon Cancer” and “Breast Cancer” by Rosenani A. Haque, Siti Fatimah Nasri, Muhammad Adnan Iqbal, Sawsan S. Al-Rawi, Seyedeh Fatemeh Jafari, Mohamed B. Khadeer Ahamed, A. M. S. Abdul Majid

“…All the compounds were tested for their cytotoxicity against human colorectal cancer (HCT 116) and breast cancer (MCF-7) cell lines. According to cell viability measurements using MTT assay, all the complexes (6-7) showed a dose-dependent cytotoxic activity against both the cell lines, whereas respective salts (4-5) proved to be inactive. …”
Get full text

Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling by Bisha Ding, Jie Li, Jia-Lin Yan, Chun-Yan Jiang, Ling-Bo Qian, Jie Pan

“…This study aims to investigate how RES affects the expression of ULBP2 and the sensitivity of breast cancer (BC) cells to NK cell cytotoxicity, along with the underlying mechanisms.MethodsThe effects of RES on ULBP2 expression were detected with qRT-PCR, western blot, flow cytometry analysis and immunohistochemistry. …”
Get full text

Human Umbilical Cord Perivascular Cells Prevent Tumor Growth in a Melanoma Tumor-Bearing Mouse Model and Modulate Breast Cancer and Melanoma Cells in a Cell Line-Dependent Manner In Vitro by Lianet Lopez, Hannah Shuster-Hyman, Eden Marco, Hasna Khan, Avishai Gasner, Aleksandra Uzelac, Brandon Wyse, Poonam Mander, Mugundhine Sangaralingam, Joseph Fish, Ariel Gorodensky, Samar Mouazz, Amanda Kauffman, Denis Gallagher, Andrée Gauthier-Fisher, Clifford L. Librach

“…Transwell coculture models were used to study the paracrine effects of multiple lines of human umbilical cord cells on human melanoma cell lines as well as breast cancer cell lines. Systemic administration of FTM and term human umbilical cord perivascular cells, but not fibroblast cells, prevented melanoma tumor growth in a tumor-bearing animal model by modulating tumor cell proliferation and systemic inflammatory mechanisms. …”
Get full text

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

“…The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2− locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. …”
Get full text

A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a r... by Philobater Bahgat Adly Awad, Basma Hussein Abdelaziz Hassan, Abanoub Adel Shafek Awad, Abdelrahman Ahmed Younis Mohamed Attaia, Kerolos Bahgat Adly Awad, Dina Mohamed Hanafy, Ahmed Gamal El Din Osman

Subjects: “…Breast cancer…”
Get full text

E2F1 activates breast stromal fibroblasts and promotes their paracrine pro-carcinogenic effects by Layla A. Al-Kharashi, Falah H. Al-Mohanna, Abdelilah Aboussekhra, Abdelilah Abousekhra

Subjects: “…Breast cancer…”
Get full text

NCAPD3-mediated ferroptosis of 2,3,5,4’-Tetrahydroxystilbene-2-O-β-D-glucoside inhibits proliferation in T47D cells by Jianfen Shen, Shuo Zhang, Shuo Zhang, Yan Song, Yan Song, Leiming Yang, Leiming Yang, Qi Huang, Qi Huang, Pengyu Wang, Pengyu Wang, Youzhi Zhang, Youzhi Zhang

Subjects: Get full text

Polymorphic variants of the <i>hOGG1, APEX1, XPD, SOD2</i>, and <i>CAT</i> genes involved in DNA repair processes and antioxidant defense and their association with breast cancer risk by А. А. Timofeeva, V. I. Minina, A. V. Torgunakova, О. А. Soboleva, R. А. Тitov, Ya. А. Zakharova, M. L. Bakanova, А. N. Glushkov

Subjects: “…breast cancer…”
Get full text

Discovery of potent allosteric antibodies inhibiting EGFR by Léxane Fournier, Lukas Pekar, Birgitta Leuthner, Harald Kolmar, Lars Toleikis, Stefan Becker

Subjects: Get full text

Polygenic diseases by Sergey Dolomatov, Walery Zukow, Anna Zhukova, Svetlana Smirnova

Subjects: Get full text